AstraZeneca's Breast-Cancer Candidate Drug Loses FDA Panel Vote
The British pharmaceutical group said it would continue to work with U.S. regulators on a review of…
wsj.com

Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.
Trend
+43.8% vs SMA 50 · +155.0% vs SMA 200
Momentum
Accumulation pattern present — more buying days than selling over the past 20 sessions. Volume conditions support gradual price improvement.
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2025 | $1.2B $1.2B–$1.2B | — | $2.35 | — | ±5% | High6 |
FY2026(current) | $1.2B $1.1B–$1.2B | ▼ -2.5% | $3.13 | ▲ +33.0% | ±12% | High5 |
FY2027 | $1.2B $1.2B–$1.2B | ▲ +5.4% | $3.46 | ▲ +10.4% | ±7% | High5 |
The British pharmaceutical group said it would continue to work with U.S. regulators on a review of…

No description available.
| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
INDV◀ | $36.78 | +7.70% | $4.6B | 18.1 | +429.3% | 1694.9% | 1500 |
| $71.11 | +0.24% | $13.8B | — | +12626.1% | — | 1500 | |
| $517.39 | -0.23% | $11.9B | — | +43205.3% | — | 1500 | |
| $87.08 | +4.40% | $11.4B | — | +3288.2% | — | 1500 | |
| $186.69 | +0.16% | $10.9B | 29.7 | +1871.5% | — | 1500 | |
| $207.75 | +0.00% | $10.6B | — | — | — | 1500 | |
| $73.48 | +4.18% | $10.3B | 50.9 | +2325815.3% | — | 1500 | |
| Sector avg | — | +2.35% | — | 32.9 | +397872.6% | 1694.9% | 1500 |